Core Insights - RespireRx Pharmaceuticals Inc. has received a grant of $1,499,869 from the NIH/NINDS to support the development of its lead GABAkine, KRM-II-81, for the treatment of epilepsy [2][17] - The company has entered into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation to enhance its neuromodulator programs [3][6] Grant Details - The NIH/NINDS grant is awarded under the Small Business Innovation Research (SBIR) program, covering the budget period from September 23, 2025, to August 31, 2026, with a total requested amount of $2,999,738 over two years [2][17] - The project aims to complete preclinical toxicology studies to support the filing of an investigational new drug application (IND) for KRM-II-81 [2][17] Patent License Agreement - The Amended and Restated Patent License Agreement includes updates on regulatory milestone payments, royalty structures, and patent cost reimbursements [6][7] - The agreement eliminates prior equity provisions in favor of a fixed exit fee tied to liquidity events, streamlining diligence and reporting obligations [6][7] Product Development - KRM-II-81 has shown significant anti-seizure activity across 34 preclinical models, with no development of pharmaco-resistance or tolerance [4][14] - The compound has also demonstrated analgesic properties comparable to commonly used analgesics without the side effects associated with opioids [5][16] Company Overview - RespireRx Group focuses on developing treatments for psychiatric and neurological disorders, including epilepsy, pain, ADHD, and obstructive sleep apnea [8][9] - The company holds exclusive licenses and patents for various chemical compounds aimed at treating a range of disorders [9] Future Directions - EndeavourRx LLC will continue to focus on the development of KRM-II-81 and other GABAkines for neurological and psychiatric disorders [3][13] - The company is also advancing its AMPAkines programs, which have shown promise in treating CNS-driven neurobehavioral and cognitive disorders [10][12]

Core Viewpoint - RespireRx Pharmaceuticals Inc. is initiating a Regulation D, Rule 506(c) exempt offering of securities, targeting a raise of up to $45 million to support its research and development efforts across its affiliated entities [1] Summary of the Offering - The financing will support ongoing and future research and development and clinical programs across RespireRx, EndeavourRx LLC, and ResolutionRx Ltd [2] Capital Allocation and Use of Proceeds - The funds will be allocated as follows: - ResolutionRx Ltd: $15 million for advancing a proprietary dronabinol formulation for obstructive sleep apnea (OSA), including PK/PD studies and a Phase 3 clinical trial [5] - EndeavourRx LLC: $25 million for developing AMPAkines and GABAkines, with funding from the U.S. Department of Defense and NIH [5] - RespireRx Pharmaceuticals Inc.: $5 million for corporate operations and intellectual property management [5] About RespireRx Group - RespireRx Group focuses on developing treatments for psychiatric and neurological disorders, including epilepsy, ADHD, spinal cord injury recovery, and OSA [2][3] - The group is developing a pipeline of new and repurposed drug products based on two platforms: neuromodulators (AMPAkines and GABAkines) and pharmaceutical cannabinoids [2] EndeavourRx LLC: Neuromodulators - EndeavourRx has developed a family of AMPAkines, including CX717 and CX1739, which have shown potential in treating CNS-driven disorders and have completed Phase 1 safety trials [4][7] - The company is also focusing on GABAkines for treatment-resistant epilepsy and non-opioid pain, with promising preclinical results [9][10] ResolutionRx Ltd: Pharmaceutical Cannabinoids - ResolutionRx is developing a new formulation of dronabinol for OSA, targeting a large patient population with no approved drug treatments [14][15] - The total budget for the dronabinol program is approximately $16.5 million, with a significant portion expected to qualify for the Australian R&D Tax Incentive [14] Research and Development Achievements - KRM-II-81, a GABAkine, has shown high anti-convulsant activity in preclinical studies and does not develop tolerance, making it a potential treatment for epilepsy [10][11] - Dronabinol has demonstrated significant improvement in OSA symptoms in previous clinical trials, indicating its potential for repurposing [14][15]